EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization.

Topics

Hepatocellular carcinoma · Unresectable hepatocellular carcinoma · Transarterial chemoembolization · durvalumab · bevacizumab · Immune checkpoint inhibitor therapy · VEGF inhibition · Progression-free survival · Overall survival · Objective response rate · Time to progression · Barcelona Clinic Liver Cancer (BCLC) staging · embolization-eligible HCC · proinflammatory tumor microenvironment · VEGF signaling pathway · PD-1/PD-L1 inhibitor · Transarterial chemoembolization · drug-eluting bead TACE · Child-Pugh class · Performance status · RECIST 1.1 · blinded independent central review · Phase III clinical trial · Placebo-controlled trial · Treatment-related adverse events · hazard ratio · standard of care · Extrahepatic metastasis · Tumor microenvironment · ICI-based combination therapy